Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

749
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
749
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation.

JACC. Advances·2026
Same author

Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practice.

American heart journal·2026
Same author

Self-supervised contrastive learning enables robust electrocardiogram-based cardiac classification.

Heart rhythm O2·2026
Same author

Hemodynamic Consequences and Clinical Outcomes With Intravenous Lidocaine Infusion in Patients With Atrial Fibrillation.

Journal of cardiovascular electrophysiology·2026
Same author

Institutional Factors and Shared Decision-Making for Atrial Fibrillation.

JAMA network open·2026
Same author

Predicting Ventricular Arrhythmia in Myocardial Ischemia Using Machine Learning.

Computing in cardiology·2026

Related Experiment Video

Updated: May 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

Anticoagulation in atrial fibrillation.

Benjamin A Steinberg1, Jonathan P Piccini

  • 1Electrophysiology Section, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA.

BMJ (Clinical Research Ed.)
|April 16, 2014
PubMed
Summary

Oral anticoagulation effectively prevents stroke in atrial fibrillation patients at moderate or high risk. Careful patient selection is crucial to balance stroke prevention benefits against bleeding risks with available treatments.

Area of Science:

  • Cardiology and Neurology
  • Pharmacology and Therapeutics

Background:

  • Atrial fibrillation significantly elevates stroke risk, a major cause of mortality and disability.
  • Oral anticoagulation is recommended for atrial fibrillation patients with moderate to high stroke risk.
  • Balancing anticoagulation benefits against bleeding risks necessitates precise patient selection.

Purpose of the Study:

  • To review the rationale and risk stratification for anticoagulation in atrial fibrillation.
  • To discuss available oral anticoagulant agents, including warfarin and novel oral anticoagulants.
  • To outline appropriate implementation and clinical considerations for anticoagulant therapy selection.

Main Methods:

  • Review of established criteria for stroke risk stratification in atrial fibrillation.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

21.6K

Related Experiment Videos

Last Updated: May 1, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.6K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

21.6K
  • Analysis of safety and efficacy data from large randomized trials of novel oral anticoagulants.
  • Discussion of clinical challenges and considerations in managing anticoagulant therapy.

    • Main Results:

    • Oral anticoagulation improves outcomes for high-risk atrial fibrillation patients.
    • Novel oral anticoagulants (direct thrombin inhibitors, factor Xa inhibitors) offer alternatives to warfarin.
    • These agents have demonstrated comparable safety and efficacy in non-valvular atrial fibrillation.

    Conclusions:

    • Appropriate patient selection is paramount for optimizing anticoagulation therapy in atrial fibrillation.
    • Understanding the nuances of warfarin and novel oral anticoagulants is key to effective management.
    • This review provides a framework for informed decision-making in anticoagulant selection and use.